Bone Biologics Co. (NASDAQ:BBLG) Short Interest Down 15.9% in February

Bone Biologics Co. (NASDAQ:BBLG) was the target of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 130,400 shares, a decline of 15.9% from the January 31st total of 155,000 shares. Based on an average daily volume of 200,800 shares, the short-interest ratio is currently 0.6 days. Approximately 24.5% of the company’s shares are sold short.

Bone Biologics Trading Down 3.4 %

Bone Biologics stock opened at $0.84 on Friday. Bone Biologics has a 52 week low of $0.71 and a 52 week high of $4.25. The stock has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.30.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.